{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T15:09:02Z","timestamp":1766243342695,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,20]]},"DOI":"10.7759\/cureus.99703","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T15:07:37Z","timestamp":1766243257000},"source":"Crossref","is-referenced-by-count":0,"title":["Chrono-Immune Neuropathy During PD-1 Blockade: A Report of a Fatal Case and Hypothesis on Circadian Modulation of Neurotoxicity"],"prefix":"10.7759","author":[{"given":"Ivan","family":"Bivolarski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras C","year":"2018","unstructured":"Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep. 2018, 18:3. 10.1007\/s11910-018-0810-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon AC","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, et al.. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:002890. 10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i2.97823","article-title":"Pembrolizumab-induced Guillain-Barr\u00e9 syndrome in triple-negative breast cancer: a case report","volume":"16","author":"Cherukuri PB","year":"2025","unstructured":"Cherukuri PB, Tayyeb M, Gaddameedi SR, Du D, Meghal T. Pembrolizumab-induced Guillain-Barr\u00e9 syndrome in triple-negative breast cancer: a case report. World J Clin Oncol. 2025, 16:97823. 10.5306\/wjco.v16.i2.97823","journal-title":"World J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain L","year":"2017","unstructured":"Spain L, Walls G, Julve M, et al.. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017, 28:377-85. 10.1093\/annonc\/mdw558","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1501327112","article-title":"Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1","volume":"112","author":"Curtis AM","year":"2015","unstructured":"Curtis AM, Fagundes CT, Yang G, et al.. Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. Proc Natl Acad Sci U S A. 2015, 112:7231-6. 10.1073\/pnas.1501327112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/07420528.2013.782315","article-title":"Crosstalk between the circadian clock circuitry and the immune system","volume":"30","author":"Cermakian N","year":"2013","unstructured":"Cermakian N, Lange T, Golombek D, Sarkar D, Nakao A, Shibata S, Mazzoccoli G. Crosstalk between the circadian clock circuitry and the immune system. Chronobiol Int. 2013, 30:870-88. 10.3109\/07420528.2013.782315","journal-title":"Chronobiol Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0008-4","article-title":"Clocking in to immunity","volume":"18","author":"Scheiermann C","year":"2018","unstructured":"Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nat Rev Immunol. 2018, 18:423-37. 10.1038\/s41577-018-0008-4","journal-title":"Nat Rev Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905080116","article-title":"The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways","volume":"116","author":"Nobis CC","year":"2019","unstructured":"Nobis CC, Dubeau Laram\u00e9e G, Kervezee L, Maurice De Sousa D, Labrecque N, Cermakian N. The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways. Proc Natl Acad Sci U S A. 2019, 116:20077-86. 10.1073\/pnas.1905080116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/0748730415577723","article-title":"Circadian clocks in the immune system","volume":"30","author":"Labrecque N","year":"2015","unstructured":"Labrecque N, Cermakian N. Circadian clocks in the immune system. J Biol Rhythms. 2015, 30:277-90. 10.1177\/0748730415577723","journal-title":"J Biol Rhythms"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","article-title":"Circadian timing in cancer treatments","volume":"50","author":"L\u00e9vi F","year":"2010","unstructured":"L\u00e9vi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010, 50:377-421. 10.1146\/annurev.pharmtox.48.113006.094626","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1440","article-title":"Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group","volume":"24","author":"Giacchetti S","year":"2006","unstructured":"Giacchetti S, Bjarnason G, Garufi C, et al.. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006, 24:3562-9. 10.1200\/JCO.2006.06.1440","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1124\/pr.116.013441","article-title":"Systems chronotherapeutics","volume":"69","author":"Ballesta A","year":"2017","unstructured":"Ballesta A, Innominato PF, Dallmann R, Rand DA, L\u00e9vi FA. Systems chronotherapeutics. Pharmacol Rev. 2017, 69:161-99. 10.1124\/pr.116.013441","journal-title":"Pharmacol Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1408886111","article-title":"A circadian gene expression atlas in mammals: implications for biology and medicine","volume":"111","author":"Zhang R","year":"2014","unstructured":"Zhang R, Lahens NF, Ballance HI, Hughes ME, Hogenesch JB. A circadian gene expression atlas in mammals: implications for biology and medicine. Proc Natl Acad Sci U S A. 2014, 111:16219-24. 10.1073\/pnas.1408886111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02704-9","article-title":"Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?","volume":"131","author":"Karabou\u00e9 A","year":"2024","unstructured":"Karabou\u00e9 A, Innominato PF, Wreglesworth NI, Duchemann B, Adam R, L\u00e9vi FA. Why does circadian timing of administration matter for immune checkpoint inhibitors' efficacy?. Br J Cancer. 2024, 131:783-96. 10.1038\/s41416-024-02704-9","journal-title":"Br J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem S","year":"2017","unstructured":"Diem S, Schmid S, Krapf M, et al.. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017, 111:176-81. 10.1016\/j.lungcan.2017.07.024","journal-title":"Lung Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley SJ","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C, et al.. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017, 106:1-7. 10.1016\/j.lungcan.2017.01.013","journal-title":"Lung Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01229-w","article-title":"Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and outcomes with nivolumab in pretreated non-small cell lung cancer: a multicenter retrospective study","volume":"37","author":"Russo A","year":"2020","unstructured":"Russo A, Russano M, Franchina T, et al.. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and outcomes with nivolumab in pretreated non-small cell lung cancer: a multicenter retrospective study. Adv Ther. 2020, 37:1145-55. 10.1007\/s12325-020-01229-w","journal-title":"Adv Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382970","article-title":"The predictive value of systemic immune-inflammation index for vascular access survival in chronic hemodialysis patients","volume":"15","author":"Ren S","year":"2024","unstructured":"Ren S, Xv C, Wang D, et al.. The predictive value of systemic immune-inflammation index for vascular access survival in chronic hemodialysis patients. Front Immunol. 2024, 15:1382970. 10.3389\/fimmu.2024.1382970","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan DB","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018, 11:955-65. 10.2147\/OTT.S153290","journal-title":"Onco Targets Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441467-chrono-immune-neuropathy-during-pd-1-blockade-a-report-of-a-fatal-case-and-hypothesis-on-circadian-modulation-of-neurotoxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T15:07:39Z","timestamp":1766243259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441467-chrono-immune-neuropathy-during-pd-1-blockade-a-report-of-a-fatal-case-and-hypothesis-on-circadian-modulation-of-neurotoxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.99703","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,20]]}}}